Compare Ascendis Pharma A/S (ASND) vs Workday Inc (WDAY) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Workday (WDAY) trades at $138.95, up 0.44% with a bullish technical signal. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $2.66 versus $2.51, continuing a trend of earnings outperformance. Revenue growth remains robust, projected to reach $9.9B in 2026, while the company maintains high gross margins of 75.77%. Recent news highlights AI-driven product growth with agentic AI ACV tripling year-over-year.

The outlook remains positive with a $157.30 analyst consensus price target representing 13% upside. Key opportunities include AI adoption driving larger expansion deals, while risks involve a pending California lawsuit over AI bias allegations and elevated valuation multiples. Operating cash flow strength at $2.46B supports continued investment in growth initiatives.